Lucie Rihova

Brno, JM, Czech Republic

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

MicroRNA Profiling of Bone Marrow Plasma Extracellular Vesicles in Multiple Myeloma, Extramedullary Disease, and Plasma Cell Leukemia.

MicroRNA Profiling of Bone Marrow Plasma Extracellular Vesicles in Multiple Myeloma, Extramedullary Disease, and Plasma Cell Leukemia.

Journal: Hematological oncology

Published: August 28, 2024

Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry.

Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry.

Journal: European journal of haematology

Published: August 08, 2024

JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia.

JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia.

Journal: Clinical hemorheology and microcirculation

Published: June 19, 2023

Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma.

Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma.

Journal: International journal of molecular sciences

Published: November 10, 2022

More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.

More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 31, 2022

Plasmacytoid Dendritic Cells in Patients with MGUS and Multiple Myeloma.

Plasmacytoid Dendritic Cells in Patients with MGUS and Multiple Myeloma.

Journal: Journal of clinical medicine

Published: July 30, 2021

The Clinical Significance of Circulating Microparticles Concerning Thrombosis in BCR/ABL1-negative Myeloproliferative Neoplasms.

The Clinical Significance of Circulating Microparticles Concerning Thrombosis in BCR/ABL1-negative Myeloproliferative Neoplasms.

Journal: In vivo (Athens, Greece)

Published: June 14, 2021

Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia.

Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia.

Journal: British journal of haematology

Published: April 26, 2021

Limited efficacy of daratumumab in multiple myeloma with extramedullary disease.

Limited efficacy of daratumumab in multiple myeloma with extramedullary disease.

Journal: Leukemia

Published: April 24, 2021

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial.

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial.

Journal: Blood cancer journal

Published: March 16, 2021

Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine.

Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine.

Journal: Blood advances

Published: November 23, 2020

Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network.

Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network.

Journal: Haematologica

Published: October 05, 2020

Showing 1-12 of 36

Last Updated: 09/26/2026